This Monday was the third day of the 2013 American Society of Hema­tol­o­gy (ASH) annual meeting, which was held in New Orleans.

More than any other day of the conference, Monday was packed with im­por­tant myeloma pre­sen­ta­tions, from 7:00 in the morning until almost 8:00 in the eve­ning.

This ASH update will summarize the oral pre­sen­ta­tion sessions about treat­ment-related myeloma studies that were held Monday morning. An ASH update that was pub­lished on Wednesday focused on the sessions that were held Monday afternoon and evening.

Monday morning started with three simultaneous …

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH).  The day was filled with oral presentation sessions from early in the morning until into the evening.

In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon.  The topics of these presentations ranged from the biology of myeloma to treat­ment options for newly diag­nosed, re­lapsed and refractory, and older patients.

This ASH update highlights most of the oral …

Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.

As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.

Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.

One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.

The myeloma study included in this session was …

This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.

Myeloma-related presentations were made during several sessions yesterday.

Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.

The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as pre­clin­i­cal and clin­i­cal studies testing new and existing treat­ments for myeloma.

During the session, research results were made avail­able for review by meeting attendees in the form …

Results from a recent Italian Phase 1/2 clinical trial indicate that the com­bi­na­tion of Pomalyst, cyclo­phos­pha­mide, and prednisone is effective and safe in re­lapsed and re­frac­to­ry multiple myeloma patients.

Overall, 51 percent of patients in the trial responded to the treat­ment, and the me­di­an pro­gres­sion-free survival time was 10.4 months. The me­di­an overall survival had not been reached yet; however, 69 percent of patients were alive one year after starting treat­ment.

The study participants had previously been treated with a me­di­an of three prior therapies, and all had re­ceived prior treatment with 

Final results from a Phase 3 study show that Pomalyst in combination with low-dose dexamethasone is effective for relapsed and refractory multiple myeloma patients not responding to treatment with Revlimid and Velcade.

Specifically, the results show that patients receiving Pomalyst (pomalidomide, Imnovid) in combination with low-dose dexamethasone (Decadron) had higher response rates and longer progression-free and overall survival than patients who received high-dose dexamethasone alone.

High-dose dexamethasone was chosen as the comparator in this study because, according to the study investigators, it was a common rescue treatment for …

Poma­lido­mide plus low-dose dexa­metha­sone dem­onstrated sig­nif­i­cantly longer median pro­gres­sion-free survival and over­all survival at a median follow-up of 10 months

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG), today announced that updated results from MM-003, a phase III multi-center, ran­dom­ized open-label study (n=455) of poma­lido­mide (marketed as POMALYST^® in the U.S. and IMNOVID^® in the E.U.) plus low-dose dexa­metha­sone, were published online ahead of print in The Lancet Oncology.

The study compared oral poma­lido­mide plus low-dose dexa­metha­sone with high-dose dexa­metha­sone in patients with refractory or re­lapsed and refractory multiple myeloma who have failed at least two prior thera­pies with both bor­tez­o­mib and lena­lido­mide, ad­min­is­tered alone or in …